These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 33040318)

  • 1. The clinical significance of circulating DSCAM-AS1 in patients with ER-positive breast cancer and construction of its competitive endogenous RNA network.
    Moradi MT; Fallahi H; Rahimi Z
    Mol Biol Rep; 2020 Oct; 47(10):7685-7697. PubMed ID: 33040318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of the long noncoding RNAs DSCAM-AS1 and MANCR is a potential diagnostic marker for breast carcinoma.
    Tahmouresi F; Razmara E; Pakravan K; Mossahebi-Mohammadi M; Rouhollah F; Montazeri M; Sarrafzadeh A; Fahimi H; Babashah S
    Biotechnol Appl Biochem; 2021 Dec; 68(6):1250-1256. PubMed ID: 33012018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA DSCAM-AS1 acts as a sponge of miR-137 to enhance Tamoxifen resistance in breast cancer.
    Ma Y; Bu D; Long J; Chai W; Dong J
    J Cell Physiol; 2019 Mar; 234(3):2880-2894. PubMed ID: 30203615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNA (lncRNA) DSCAM-AS1 is upregulated in breast cancer.
    Tarighi M; Khalaj-Kondori M; Hosseinzadeh A; Abtin M
    Breast Dis; 2021; 40(2):63-68. PubMed ID: 33554879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression.
    Niknafs YS; Han S; Ma T; Speers C; Zhang C; Wilder-Romans K; Iyer MK; Pitchiaya S; Malik R; Hosono Y; Prensner JR; Poliakov A; Singhal U; Xiao L; Kregel S; Siebenaler RF; Zhao SG; Uhl M; Gawronski A; Hayes DF; Pierce LJ; Cao X; Collins C; Backofen R; Sahinalp CS; Rae JM; Chinnaiyan AM; Feng FY
    Nat Commun; 2016 Sep; 7():12791. PubMed ID: 27666543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DSCAM-AS1 up-regulation in invasive ductal carcinoma of breast and assessment of its potential as a diagnostic biomarker.
    Khorshidi H; Azari I; Oskooei VK; Taheri M; Ghafouri-Fard S
    Breast Dis; 2019; 38(1):25-30. PubMed ID: 30594914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
    Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
    Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
    [No Abstract]   [Full Text] [Related]  

  • 8. DSCAM-AS1 promotes tumor growth of breast cancer by reducing miR-204-5p and up-regulating RRM2.
    Liang WH; Li N; Yuan ZQ; Qian XL; Wang ZH
    Mol Carcinog; 2019 Apr; 58(4):461-473. PubMed ID: 30457164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing DSCAM-AS1 suppresses the growth and invasion of ER-positive breast cancer cells by downregulating both DCTPP1 and QPRT.
    Yue Z; Shusheng J; Hongtao S; Shu Z; Lan H; Qingyuan Z; Shaoqiang C; Yuanxi H
    Aging (Albany NY); 2020 Jul; 12(14):14754-14774. PubMed ID: 32716908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DSCAM-AS1 regulates the G
    Sun W; Li AQ; Zhou P; Jiang YZ; Jin X; Liu YR; Guo YJ; Yang WT; Shao ZM; Xu XE
    Cancer Med; 2018 Dec; 7(12):6137-6146. PubMed ID: 30430768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer.
    Fan CN; Ma L; Liu N
    J Transl Med; 2018 Sep; 16(1):264. PubMed ID: 30261893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum LncRNA-ATB and FAM83H-AS1 as diagnostic/prognostic non-invasive biomarkers for breast cancer.
    El-Ashmawy NE; Hussien FZ; El-Feky OA; Hamouda SM; Al-Ashmawy GM
    Life Sci; 2020 Oct; 259():118193. PubMed ID: 32763293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance.
    Feng J; Wen T; Li Z; Feng L; Zhou L; Yang Z; Xu L; Shi S; Hou K; Shen J; Han X; Teng Y
    Aging (Albany NY); 2020 Oct; 12(20):20658-20683. PubMed ID: 33098638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long noncoding RNA DSCAM-AS1 is associated with poor clinical prognosis and contributes to melanoma development by sponging miR-136.
    Huang YL; Xu Q; Wang X
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(7):2888-2897. PubMed ID: 31002140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA DSCAM-AS1: A Pivotal Therapeutic Target in Cancer.
    Hu C
    Mini Rev Med Chem; 2023; 23(5):530-536. PubMed ID: 35996247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer.
    Zhang K; Luo Z; Zhang Y; Zhang L; Wu L; Liu L; Yang J; Song X; Liu J
    Cancer Biomark; 2016 Jun; 17(2):187-94. PubMed ID: 27540977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long noncoding RNA DSCAM-AS1 functions as an oncogene in non-small cell lung cancer by targeting BCL11A.
    Liao J; Xie N
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1087-1092. PubMed ID: 30779076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long non-coding RNA DSCAM-AS1 indicates a poor prognosis and modulates cell proliferation, migration and invasion in ovarian cancer via upregulating SOX4.
    Li Y; Hao J; Jiang YM; Liu Y; Zhang SH
    Eur Rev Med Pharmacol Sci; 2019 May; 23(10):4143-4148. PubMed ID: 31173284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interplay of lncRNA H19/miR-675 and lncRNA NEAT1/miR-204 in breast cancer.
    Müller V; Oliveira-Ferrer L; Steinbach B; Pantel K; Schwarzenbach H
    Mol Oncol; 2019 May; 13(5):1137-1149. PubMed ID: 30803129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DSCAM-AS1-Driven Proliferation of Breast Cancer Cells Involves Regulation of Alternative Exon Splicing and 3'-End Usage.
    Elhasnaoui J; Miano V; Ferrero G; Doria E; Leon AE; Fabricio ASC; Annaratone L; Castellano I; Sapino A; De Bortoli M
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32503257
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.